The COVID-19 pandemic caught society unprepared. The lack of therapeutic agents for coronaviruses led to a scramble to investigate approved medications for repurposing against SARS-CoV-2. Successes were achieved with immunomodulatory agents for the inflammatory disease processes of COVID-19, but the antiviral search has been less productive. One of the more interesting therapeutic candidates investigated is fluvoxamine.
